
News|Articles|November 5, 2014
Vaccine Strategies in Follicular Lymphoma
Author(s)Joshua Brody, MD
Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses vaccine strategies in follicular lymphoma.
Advertisement
Clinical Pearls
Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses vaccine strategies in follicular lymphoma. Brody presented on this topic at the 2014 Chemotherapy Foundation Symposium.
- First generations of lymphoma vaccines looked promising, but were not efficacious enough to become standard therapies.
- New lymphoma vaccines take a more holistic perspective targeting any tumor-specific or tumor-associated antigens.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5







































